Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Laura Faden Garabedian, Ph.D.

Concepts (119)

Back to Profile
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Comparative Effectiveness Research320226791.270 Why?
Deductibles and Coinsurance220213150.820 Why?
Diabetes Mellitus5202157020.750 Why?
Insurance, Health4202024910.660 Why?
Blood Glucose Self-Monitoring120194300.550 Why?
Bariatric Surgery120229350.430 Why?
Telemedicine2201928440.370 Why?
Insurance Coverage2202018910.340 Why?
Drug Approval520107420.330 Why?
Insurance, Pharmaceutical Services320103360.310 Why?
Quality Assurance, Health Care1201822120.300 Why?
Health Care Reform1201612580.290 Why?
Patient Acceptance of Health Care2201930210.280 Why?
Quality of Health Care2201843650.280 Why?
Blood Glucose1201962360.250 Why?
Attitude of Health Personnel1201838440.240 Why?
Insurance, Health, Reimbursement220093950.240 Why?
Product Surveillance, Postmarketing220094390.240 Why?
Research Personnel120085710.220 Why?
Formularies as Topic32009910.210 Why?
Tobacco, Smokeless120231290.210 Why?
Primary Health Care1201845370.210 Why?
Interviews as Topic2201825330.200 Why?
Medical Savings Accounts12020320.190 Why?
Minority Groups1200811970.180 Why?
Drug Utilization Review120112450.180 Why?
Cost Sharing220204100.170 Why?
Economic Competition120102130.170 Why?
Government Programs120112770.160 Why?
Insurance Carriers120201530.160 Why?
Patient Protection and Affordable Care Act2202012060.160 Why?
Intrauterine Devices120191190.160 Why?
Off-Label Use120091680.150 Why?
Drug Industry220107420.140 Why?
Eligibility Determination120204030.140 Why?
Influenza Vaccines120237400.140 Why?
Costs and Cost Analysis1202116750.130 Why?
Health Services120117570.130 Why?
Patient Selection1200842110.130 Why?
New England1201810210.130 Why?
Drug Design1201010860.130 Why?
Internationality2200810040.130 Why?
Pharmacoepidemiology120083220.120 Why?
Burnout, Professional120236850.120 Why?
Risk Management120085710.120 Why?
Focus Groups1201813080.120 Why?
Influenza, Human1202314760.110 Why?
Program Evaluation1201124840.100 Why?
Humans2420247392190.100 Why?
Research Design1200859590.100 Why?
Pharmaceutical Preparations2201010660.100 Why?
Insurance Claim Review120167200.100 Why?
Drug Monitoring120089610.100 Why?
International Cooperation1200814200.100 Why?
Equipment Design1201935760.100 Why?
Self Care120157870.090 Why?
Students, Medical1202318500.090 Why?
Qualitative Research1201826560.090 Why?
United States Food and Drug Administration4201015840.090 Why?
Health Services Accessibility2200751280.080 Why?
Health Expenditures1202123480.080 Why?
Poverty1202026260.080 Why?
United States82020695680.080 Why?
Developing Countries1201027790.080 Why?
Quality Indicators, Health Care1201818280.080 Why?
Hypoglycemic Agents1202028610.080 Why?
Antipsychotic Agents1201130550.070 Why?
Drug Prescriptions1200716370.070 Why?
Massachusetts2201986680.070 Why?
Regression Analysis1201464510.060 Why?
Prejudice120085720.060 Why?
Socioeconomic Factors1201677260.050 Why?
Schizophrenia1201168670.050 Why?
Time Factors32016400400.050 Why?
Immunotherapy1200543890.040 Why?
Patents as Topic120101020.040 Why?
Middle Aged420202128330.040 Why?
Data Collection1200833400.040 Why?
Antibodies, Monoclonal1200592590.040 Why?
Cardiovascular Diseases12024150690.040 Why?
Aged220211626670.040 Why?
Financing, Personal120203100.040 Why?
Pharmacopoeias as Topic12007170.040 Why?
Follow-Up Studies12019389410.040 Why?
European Union120081570.040 Why?
Clinical Trials as Topic2200878970.040 Why?
Female620203788080.040 Why?
Pharmacy and Therapeutics Committee1200690.040 Why?
Male520203489670.030 Why?
Longitudinal Studies22023138800.030 Why?
Cost-Benefit Analysis2201054620.030 Why?
France120075160.030 Why?
Government Agencies120061560.030 Why?
Adolescent32020854090.030 Why?
Chemistry, Pharmaceutical120052850.030 Why?
Hybridomas120054520.030 Why?
State Medicine120062190.030 Why?
Marketing120062080.030 Why?
Japan1200813510.030 Why?
Pandemics2202482740.030 Why?
Biotechnology120052780.030 Why?
Government Regulation120085240.030 Why?
Safety1200811850.030 Why?
Netherlands1200721690.030 Why?
Vaccination1202332320.020 Why?
Adult320202133750.020 Why?
Emotions1202326420.020 Why?
Retrospective Studies12019766320.020 Why?
Reimbursement Mechanisms120066700.020 Why?
Physicians1200845380.020 Why?
Medicare2200964970.020 Why?
Patient Participation1200714410.020 Why?
Evidence-Based Medicine1200936060.020 Why?
Anxiety1201942540.020 Why?
Child22023770290.010 Why?
Young Adult22020562520.010 Why?
Health Care Costs1200732260.010 Why?
Neoplasms12005214990.000 Why?
Animals120051683580.000 Why?
Garabedian's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (119)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2024 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.